Group 1 - The core point of the article is that YuanDa Pharmaceutical announced the successful completion of Phase II clinical trials for its innovative traditional Chinese medicine GPN01360, aimed at treating depression, marking a significant milestone in the company's otolaryngology sector [1] - Depression, also known as depressive disorder, has a high recurrence rate of 75%-90% and is a lifelong condition, representing a major public health issue globally, with approximately 332 million people affected, leading to a prevalence rate of 4.0%, and an adult prevalence rate of 5.7% according to WHO [1] - Current clinical cure rates for depression are below 30%, indicating a substantial unmet clinical need, which GPN01360 aims to address by providing a new treatment option [1] Group 2 - The company is focusing on traditional Chinese medicine as a key strategic direction within its otolaryngology sector, leveraging its core advantages in chronic disease treatment [2] - YuanDa Pharmaceutical is expanding its product matrix in the otolaryngology field while strategically entering cardiovascular and neurological treatment areas with competitive traditional Chinese medicine products [2] - The company aims to systematically broaden the treatment boundaries of chronic disease management and open new growth avenues through its strong product pipeline [2]
远大医药：中药创新药GPN01360 II期临床研究成功达到临床终点